Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCX7353 single-dose for acute hereditary angioedema attacks (phase 2, randomized, double-blind, placebo-controlled, dose-ranging)
2016-001424-55Phase 2Completed
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hereditary angioedema (HAE) comparing BCX7353 single oral dose with Placebo single oral dose (2 arms). Primary endpoint: Primary: 3-symptom composite VAS score at 4 hours post-dose. Started Mar 2017; status: completed.
02
Drugs
berotralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2016-001424-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001424-55.